Revvity (NYSE:RVTY) Announces Quarterly Earnings Results

Revvity (NYSE:RVTY) issued its earnings results on Friday. The company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.37 by $0.05, RTT News reports. Revvity had a net margin of 9.34% and a return on equity of 7.42%. During the same period in the previous year, the firm posted $1.25 earnings per share. Revvity updated its FY 2025 guidance to 4.900-5.000 EPS.

Revvity Trading Up 0.3 %

NYSE:RVTY traded up $0.39 during trading hours on Friday, hitting $127.23. 528,813 shares of the company were exchanged, compared to its average volume of 872,222. The stock has a market capitalization of $15.48 billion, a price-to-earnings ratio of 61.58, a price-to-earnings-growth ratio of 4.09 and a beta of 1.03. Revvity has a one year low of $97.32 and a one year high of $129.50. The company has a fifty day simple moving average of $116.60 and a 200 day simple moving average of $118.60. The company has a current ratio of 3.56, a quick ratio of 2.97 and a debt-to-equity ratio of 0.40.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be issued a dividend of $0.07 per share. The ex-dividend date is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.22%. Revvity’s dividend payout ratio (DPR) is presently 13.53%.

Revvity announced that its board has authorized a share buyback plan on Monday, November 4th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 6.5% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Activity

In other news, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the sale, the insider now directly owns 19,652 shares in the company, valued at $2,295,550.12. This represents a 21.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on RVTY shares. Robert W. Baird lifted their price objective on shares of Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Barclays lowered their price target on Revvity from $140.00 to $135.00 and set an “overweight” rating for the company in a report on Monday, November 25th. Raymond James reduced their price objective on Revvity from $146.00 to $140.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Bank of America raised Revvity from a “neutral” rating to a “buy” rating and set a $138.00 target price for the company in a research note on Friday, December 13th. Finally, Leerink Partners raised their price target on shares of Revvity from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Five analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Revvity has a consensus rating of “Moderate Buy” and an average target price of $132.00.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.